drugset / Trial / NCT00343668
S-1 and Irinotecan Combination Chemotherapy for Advanced Gastric Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary goal of this phase II trial is to evaluate the response rate of combination chemotherapy with S-1 and Irinotecan in patients with advanced gastric cancer as a first-line therapy.
Timeline
- Start
- 2005-09
- Primary completion
- 2007-03
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 150 mg/m2 | Intravenous |
| Subject | S-1 | Small molecule | 40 mg/m2 | Oral |